The Year in Atherothrombosis

Journal of the American College of Cardiology

Volumn 51, Issue 9, 2008, Pages 944-955

  Sanz, Javier ^a   Moreno, Pedro R ^a   Fuster, Valentin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; FONDAPARINUX; HEMOGLOBIN A1C; HIRULOG; INDAPAMIDE; INSULIN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; PIOGLITAZONE; PRASUGREL; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; STATINE DERIVATIVE; TORCETRAPIB;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; CLINICAL TRIAL; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; SYMPTOMATOLOGY; THROMBOSIS;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; FIBRINOLYTIC AGENTS; HEALTH PROMOTION; HUMANS; OBESITY; RISK ASSESSMENT; THROMBOSIS;

EID: 39749148340     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.12.018     Document Type: Review

References (101)

1. Davies A.R., Smeeth L., and Grundy E.M. Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996-2005. Eur Heart J 28 (2007) 2142-2147
2. Ford E.S., Ajani U.A., Croft J.B., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 356 (2007) 2388-2398
3. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
4. Steg P.G., Bhatt D.L., Wilson P.W., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 (2007) 1197-1206
5. Gibbons R.J. Leading the elephant out of the corner: the future of health care: presidential address at the American Heart Association 2006 Scientific Sessions. Circulation 115 (2007) 2221-2230
6. Fuster V., Voute J., Hunn M., and Smith Jr. S.C. Low priority of cardiovascular and chronic diseases on the global health agenda: a cause for concern. Circulation 116 (2007) 1966-1970
7. Fox K.A.A., Steg P.G., Eagle K.A., et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 297 (2007) 1892-1900
8. Fox C.S., Coady S., Sorlie P.D., et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart study. Circulation 115 (2007) 1544-1550
9. Hayman L.L., Meininger J.C., Daniels S.R., et al. Primary prevention of cardiovascular disease in nursing practice: focus on children and youth: a scientific statement from the American Heart Association Committee on Atherosclerosis, Hypertension, and Obesity in Youth of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity, and Metabolism. Circulation 116 (2007) 344-357
10. Balkau B., Deanfield J.E., Despres J.-P., et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168 000 primary care patients in 63 countries. Circulation 116 (2007) 1942-1951
11. Frieden T.R., and Bloomberg M.R. How to prevent 100 million deaths from tobacco. Lancet 369 (2007) 1758-1761
12. Kallio K., Jokinen E., Raitakari O.T., et al. Tobacco smoke exposure is associated with attenuated endothelial function in 11-year-old healthy children. Circulation 115 (2007) 3205-3212
13. Schroeder S.A. Shattuck lecture. We can do better-improving the health of the American people. N Engl J Med 357 (2007) 1221-1228
14. Keevil J.G., Cullen M.W., Gangnon R., McBride P.E., and Stein J.H. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation 115 (2007) 1363-1370
15. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 28 (2007) 2375-2414
16. World Health Organization. Prevention of cardiovascular disease: pocket guidelines for assessment and management of cardiovascular risk. http://www.who.int/cardiovascular_diseases/guidelines/PocketGL.ENGLISH.A FR-D-E.rev1.pdf Accessed December 19, 2007
17. Sniderman A.D., Holme I., Aastveit A., Furberg C., Walldius G., and Jungner I. Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease. Am J Cardiol 100 (2007) 217-221
18. Nordestgaard B.G., Benn M., Schnohr P., and Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 (2007) 299-308
19. See R., Abdullah S.M., McGuire D.K., et al. The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart study. J Am Coll Cardiol 50 (2007) 752-759
20. Ingelsson E., Sullivan L.M., Fox C.S., et al. Burden and prognostic importance of subclinical cardiovascular disease in overweight and obese individuals. Circulation 116 (2007) 375-384
21. Pou K.M., Massaro J.M., Hoffmann U., et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart study. Circulation 116 (2007) 1234-1241
22. Gustafson B., Hammarstedt A., Andersson C.X., and Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 27 (2007) 2276-2283
23. Halton T.L., Willett W.C., Liu S., et al. Low-carbohydrate-diet score and the risk of coronary heart disease in women. N Engl J Med 355 (2006) 1991-2002
24. Barr E.L., Zimmet P.Z., Welborn T.A., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle study (AusDiab). Circulation 116 (2007) 151-157
25. Liu J., Grundy S.M., Wang W., et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 153 (2007) 552-558
26. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49 (2007) 403-414
27. Ridker P.M., Buring J.E., Rifai N., and Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 297 (2007) 611-619
28. Guttormsen B.N., Stein J.H., McBride P.E., Cullen M.W., Gangnon R., and Keevil J.G. Rationale for targeted rather than population based screening with C-reactive protein using the National Health and Nutrition Examination Survey (1999 to 2002). Am J Cardiol 100 (2007) 1130-1133
29. Cao J.J., Arnold A.M., Manolio T.A., et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health study. Circulation 116 (2007) 32-38
30. Lange L.A., Carlson C.S., Hindorff L.A., et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 296 (2006) 2703-2711
31. Emberson J.R., Ng L.L., Armitage J., Bowman L., Parish S., and Collins R. N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF Heart Protection study. J Am Coll Cardiol 49 (2007) 311-319
32. Olsen M.H., Hansen T.W., Christensen M.K., et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 28 (2007) 1374-1381
33. Ingelsson E., Pencina M.J., Tofler G.H., et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring study. Circulation 116 (2007) 984-992
34. 2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 116 (2007) 1396-1403
35. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006) 2631-2639
36. Tzoulaki I., Murray G.D., Lee A.J., Rumley A., Lowe G.D., and Fowkes F.G. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery study. Circulation 115 (2007) 2119-2127
37. Shantsila E., Watson T., and Lip G.Y.H. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 49 (2007) 741-752
38. Sorrentino S.A., Bahlmann F.H., Besler C., et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 116 (2007) 163-173
39. Levy A.P., Purushothaman K.R., Levy N.S., et al. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 101 (2007) 106-110
40. Morgan T.M., Krumholz H.M., Lifton R.P., and Spertus J.A. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 297 (2007) 1551-1561
41. Arnett D.K., Baird A.E., Barkley R.A., et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 115 (2007) 2878-2901
42. Samani N.J., Erdmann J., Hall A.S., et al. Genomewide association analysis of coronary artery disease. N Engl J Med 357 (2007) 443-453
43. Scott L.J., Mohlke K.L., Bonnycastle L.L., et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316 (2007) 1341-1345
44. Kathiresan S., Larson M.G., Keyes M.J., et al. Assessment by cardiovascular magnetic resonance, electron beam computed tomography, and carotid ultrasonography of the distribution of subclinical atherosclerosis across Framingham risk strata. Am J Cardiol 99 (2007) 310-314
45. Kim L.G., Scott R.A.P., Ashton H.A., Thompson S.G., and Multicentre Aneurysm Screening Study Group. A sustained mortality benefit from screening for abdominal aortic aneurysm. Ann Intern Med 146 (2007) 699-706
46. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., and Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007) 459-467
47. Lamina C., Meisinger C., Heid I.M., et al. Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. Eur Heart J 27 (2006) 2580-2587
48. Sen S., Hinderliter A., Sen P.K., et al. Aortic arch atheroma progression and recurrent vascular events in patients with stroke or transient ischemic attack. Circulation 116 (2007) 928-935
49. Greenland P., Bonow R.O., Brundage B.H., et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). J Am Coll Cardiol 49 (2007) 378-402
50. Budoff M.J., Shaw L.J., Liu S.T., et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 49 (2007) 1860-1870
51. Rozanski A., Gransar H., Wong N.D., et al. Clinical outcomes after both coronary calcium scanning and exercise myocardial perfusion scintigraphy. J Am Coll Cardiol 49 (2007) 1352-1361
52. Cassidy-Bushrow A.E., Bielak L.F., Sheedy II P.F., et al. Coronary artery calcification progression is heritable. Circulation 116 (2007) 25-31
53. Hoffmann B., Moebus S., Mohlenkamp S., et al. Residential exposure to traffic is associated with coronary atherosclerosis. Circulation 116 (2007) 489-496
54. Meijboom W.B., van Mieghem C.A.G., Mollet N.R., et al. 64-slice computed tomography coronary angiography in patients with high, intermediate, or low pretest probability of significant coronary artery disease. J Am Coll Cardiol 50 (2007) 1469-1475
55. Butler J., Shapiro M., Reiber J., et al. Extent and distribution of coronary artery disease: a comparative study of invasive versus noninvasive angiography with computed angiography. Am Heart J 153 (2007) 378-384
56. Cheruvu P.K., Finn A.V., Gardner C., et al. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. J Am Coll Cardiol 50 (2007) 940-949
57. Min J.K., Shaw L.J., Devereux R.B., et al. Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol 50 (2007) 1161-1170
58. Kim W.Y., Astrup A.S., Stuber M., et al. Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathy. Circulation 115 (2007) 228-235
59. Tahara N., Kai H., Yamagishi S., et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 49 (2007) 1533-1539
60. Rudd J.H., Myers K.S., Bansilal S., et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol 50 (2007) 892-896
61. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 48 (2006) 1825-1831
62. Nicholls S.J., Tuzcu E.M., Wolski K., et al. Coronary artery calcification and changes in atheroma burden in response to established medical therapies. J Am Coll Cardiol 49 (2007) 263-270
63. Kubo T., Imanishi T., Takarada S., et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol 50 (2007) 933-939
64. Amirbekian V., Lipinski M.J., Briley-Saebo K.C., et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 104 (2007) 961-966
65. Hyafil F., Cornily J.C., Feig J.E., et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 13 (2007) 636-641
66. Kaufmann B.A., Sanders J.M., Davis C., et al. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 116 (2007) 276-284
67. Flaumenhaft R., Tanaka E., Graham G.J., et al. Localization and quantification of platelet-rich thrombi in large blood vessels with near-infrared fluorescence imaging. Circulation 115 (2007) 84-93
68. Niinikoski H., Lagstrom H., Jokinen E., et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation 116 (2007) 1032-1040
69. Hu G., Tuomilehto J., Borodulin K., and Jousilahti P. The joint associations of occupational, commuting, and leisure-time physical activity, and the Framingham risk score on the 10-year risk of coronary heart disease. Eur Heart J 28 (2007) 492-498
70. Boden W.E., O'Rourke R.A., Teo K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007) 1503-1516
71. Kereiakes D.J., Teirstein P.S., Sarembock I.J., et al. The truth and consequences of the COURAGE trial. J Am Coll Cardiol 50 (2007) 1598-1603
72. Hueb W., Lopes N.H., Gersh B.J., et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115 (2007) 1082-1089
73. Rasmussen J.N., Chong A., and Alter D.A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297 (2007) 177-186
74. Wood D.A. Clinical reality of coronary prevention in Europe: a comparison of EUROASPIRE I, II and III surveys. http://www.cardiosource.com/rapidnewssummaries/index.asp?EID=27&DoW= Sun&SumID=216 Accessed December 19, 2007
75. Ford I., Murray H., Packard C.J., Shepherd J., Macfarlane P.W., and Cobbe S.M. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357 (2007) 1477-1486
76. Crouse III J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 297 (2007) 1344-1353
77. Leeper N.J., Ardehali R., deGoma E.M., and Heidenreich P.A. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation 116 (2007) 613-618
78. Afilalo J., Majdan A.A., and Eisenberg M.J. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 93 (2007) 914-921
79. Chan P.S., Nallamothu B.K., Gurm H.S., Hayward R.A., and Vijan S. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 115 (2007) 2398-2409
80. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
81. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
82. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
83. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
84. Bots M.L., Visseren F.L., Evans G.W., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370 (2007) 153-160
85. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
86. Tardif J.C., Gregoire J., L'Allier P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007) 1675-1682
87. Ibanez B., Vilahur G., Cimmino G., et al. Rapid change in plaque size, composition and molecular footprint following recombinant ApoA-IMilano (ETC-216) administration. J Am Coll Cardiol (2008) In press
88. Bhatt D.L., Flather M.D., Hacke W., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007) 1982-1988
89. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
90. Mehta S.R., Granger C.B., Eikelboom J.W., et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 50 (2007) 1742-1751
91. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
92. Anand S., Yusuf S., Xie C., et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357 (2007) 217-227
93. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
94. Psaty B.M., and Furberg C.D. Rosiglitazone and cardiovascular risk. N Engl J Med 356 (2007) 2522-2524
95. Diamond G.A., Bax L., and Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 147 (2007) 578-581
96. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
97. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
98. Rosen C.J. The rosiglitazone story-lessons from an FDA advisory committee meeting. N Engl J Med 357 (2007) 844-846
99. Food and Drug Administration. Information for Healthcare Professionals. Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl). http://www.fda.gov/cder/drug/InfoSheets/HCP/rosiglitazone200707HCP.htm#2 007_5 Accessed December 19, 2007
100. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
101. Patel A., MacMahon S., Chalmers J., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840